title: Abatacept in B7-1-positive proteinuric kidney disease.
abstract: Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.
authors.affiliation: From the Department of Medicine, Massachusetts General Hospital and Harvard Medical School (C.-C.Y., A.W., S.H., D.B., M.A.A., A.G., P.M.), Department of Pathology, Brigham and Women's Hospital and Harvard Medical School (A.W.), and Division of Nephrology, Children's Hospital Boston (P.F.) - all in Boston; the Graduate Institute of Medicine, College of Medicine (C.-C.Y.), and Department of Internal Medicine (J.-M.C., H.-C.C.), Kaohsiung Medical University, Kaohsiung, Taiwan; the Division of Nephrology and Hypertension (A.F., D.M., M.H.F., C.F., V.G.) and Lilian Jean Kaplan Division of Kidney-Pancreas Transplantation, Miami Transplant Institute, Department of Surgery (J.S., L.C., G.C., G.W.B.), University of Miami Miller School of Medicine, Miami; the Division of Nephrology, Mount Sinai School of Medicine, New York (K.N.C.); and Pediatric Nephrology, Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (J.O.).
authors.forename: Chih-Chuan
authors.initials: CC
authors.lastname: Yu
authors.forename: Alessia
authors.initials: A
authors.lastname: Fornoni
authors.forename: Astrid
authors.initials: A
authors.lastname: Weins
authors.forename: Samy
authors.initials: S
authors.lastname: Hakroush
authors.forename: Dony
authors.initials: D
authors.lastname: Maiguel
authors.forename: Junichiro
authors.initials: J
authors.lastname: Sageshima
authors.forename: Linda
authors.initials: L
authors.lastname: Chen
authors.forename: Gaetano
authors.initials: G
authors.lastname: Ciancio
authors.forename: Mohd Hafeez
authors.initials: MH
authors.lastname: Faridi
authors.forename: Daniel
authors.initials: D
authors.lastname: Behr
authors.forename: Kirk N
authors.initials: KN
authors.lastname: Campbell
authors.forename: Jer-Ming
authors.initials: JM
authors.lastname: Chang
authors.forename: Hung-Chun
authors.initials: HC
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Oh
authors.forename: Christian
authors.initials: C
authors.lastname: Faul
authors.forename: M Amin
authors.initials: MA
authors.lastname: Arnaout
authors.forename: Paolo
authors.initials: P
authors.lastname: Fiorina
authors.forename: Vineet
authors.initials: V
authors.lastname: Gupta
authors.forename: Anna
authors.initials: A
authors.lastname: Greka
authors.forename: George W
authors.initials: GW
authors.lastname: Burke
authors.forename: Peter
authors.initials: P
authors.lastname: Mundel
mesh_terms: D000069594:Abatacept; D000293:Adolescent; D000328:Adult; D018122:B7-1 Antigen / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D002648:Child; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D050199:Podocytes / Q000187:drug effects / Q000378:metabolism; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D055815:Young Adult
chemical_list: D018122:B7-1 Antigen; D015415:Biomarkers; D018796:Immunoconjugates; D000069594:Abatacept